Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial

@inproceedings{Afshar2014TopiramateAI,
  title={Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial},
  author={Hamid Afshar and Shahla Akuchekian and Behzad Mahaky and Elham Zarean},
  booktitle={Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences},
  year={2014}
}
BACKGROUND This study aimed to assess the efficacy of topiramate, a glutamate-modulating agent, in patients with treatment-resistant obsessive-compulsive disorder (OCD) as an adjunct to serotonin reuptake inhibitors (SRIs). MATERIALS AND METHODS Thirty-eight patients with refractory OCD, were randomly assigned to receive topiramate or placebo. This study was designed as a 12 weeks, double-blind, placebo-controlled trial. Primary outcome measures were the change in Yale-Brown Obsessive… CONTINUE READING